ABBV supply chain intelligence for AbbVie Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
AbbVie Inc. (ABBV) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| IRWD | Ironwood Pharmaceuticals, Inc. | 92% | Reciprocal relationship from IRWD graph: Reciprocal relationship from ABBV graph: Reciprocal relationship from IRWD graph: The Company records royalties on sales of CONSTELLA in Canada and LINZESS in… |
| XLO | Xilio Therapeutics, Inc. | 92% | Reciprocal relationship from XLO graph: upfront and milestone payments under our collaboration and license agreements with AbbVie |
| ALDX | Aldeyra Therapeutics, Inc. | 90% | Reciprocal relationship from ALDX graph: Reciprocal relationship from ABBV graph: Reciprocal relationship from ALDX graph: Outside of the United States, the Company would be eligible to receive tiere… |
| IMNM | Immunome, Inc. | 85% | Reciprocal relationship from IMNM graph: generated any revenue from product sales and do not expect to do so for the foreseeable future. To date, we have generated our revenue through a Collaboration… |
| CTMX | CytomX Therapeutics, Inc. | 80% | Reciprocal relationship from CTMX graph: For instance, in March 2023, AbbVie terminated our 2016 CD71 License and Collaboration Agreement |
| ESGL | ESGL Holdings Limited | 62% | Reciprocal relationship from ESGL graph: ), STMicroelectronics Pte Ltd (“STMicro”) and Systems on Silicon Manufacturing Company Pte Ltd (“SSMC”); (iii) pharmaceutical corporations such as AbbVie Oper… |
| IRON | Disc Medicine, Inc. | 62% | Reciprocal relationship from IRON graph: Reciprocal relationship from ABBV graph: Reciprocal relationship from IRON graph: s, we may be required to provide preclinical and clinical data showing the c… |
| LCTX | Lineage Cell Therapeutics, Inc. | 62% | Reciprocal relationship from LCTX graph: Reciprocal relationship from ABBV graph: Reciprocal relationship from LCTX graph: Reciprocal relationship from ABBV graph: Reciprocal relationship from LCTX g… |
| NBP | NovaBridge Biosciences | 62% | Reciprocal relationship from NBP graph: Reciprocal relationship from ABBV graph: Reciprocal relationship from NBP graph: roduction, particularly in scaling up or out, validating the production proces… |
| PHVS | Pharvaris N.V. | 62% | Reciprocal relationship from PHVS graph: ates, the reimbursement for our products may be reduced compared with the United States and may be insufficient to generate commercially reasonable revenues a… |
| RGNX | REGENXBIO Inc. | 62% | Reciprocal relationship from RGNX graph: Reciprocal relationship from ABBV graph: Reciprocal relationship from RGNX graph: Reciprocal relationship from ABBV graph: Reciprocal relationship from RGNX g… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| IRON | Disc Medicine, Inc. | 92% | Reciprocal relationship from IRON graph: Under the AbbVie Agreement, we obtained an exclusive, worldwide license, with the right to sublicense to commercial pharmaceutical and biopharmaceutical compa… |
| U-S-WHOLESALERS | U-S-WHOLESALERS | 92% | three U.S. wholesalers accounted for 78 % as of March 31, 2026 and 84 % as of December 31, 2025, and substantially all of AbbVie’s pharmaceutical product net revenues in the United States were to the… |
| SION | Sionna Therapeutics, Inc. | 90% | Reciprocal relationship from SION graph: We have entered into license agreements with Sanofi and AbbVie, pursuant to which, among other things, we have secured exclusive licenses for certain intellec… |
| JANSSEN-BIOTECH-INC | JANSSEN-BIOTECH-INC | 85% | ended March 31, 2026 and $ 242 million for the three months ended March 31, 2025. Sales and marketing and development costs for the three months ended March 31, 2026 and 2025 were insignificant. Coll… |
| JNJ | Johnson & Johnson | 85% | Reciprocal relationship from JNJ graph: Reciprocal relationship from ABBV graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from ABBV graph: ended March 31, 2026 and $ 242 millio… |
| ROCHE-GROUP | ROCHE-GROUP | 85% | rs. The upfront payment of $ 650 million was recorded in acquired IPR&D and milestones expense in the condensed consolidated statement of earnings in the first quarter of 2026. AbbVie could make addi… |
| ARGX | argenx SE | 80% | Reciprocal relationship from ARGX graph: We currently have collaborative research relationships with various pharmaceutical companies such as AbbVie |
| CTMX | CytomX Therapeutics, Inc. | 80% | Reciprocal relationship from CTMX graph: Reciprocal relationship from ABBV graph: Reciprocal relationship from CTMX graph: For instance, in March 2023, AbbVie terminated our 2016 CD71 License and Col… |
| JNJ | Johnson & Johnson | 72% | ended March 31, 2026 and $ 242 million for the three months ended March 31, 2025. Sales and marketing and development costs for the three months ended March 31, 2026 and 2025 were insignificant. Coll… |
| EXECUTIVE-OVERVIEW-COMPANY | EXECUTIVE-OVERVIEW-COMPANY | 62% | ying notes appearing in Item 1, “Financial Statements and Supplementary Data.” EXECUTIVE OVERVIEW Company Overview AbbVie is a global, diversified research-based biopharmaceutical company positioned … |
| NIMBLE-THERAPEUTICS-INC | NIMBLE-THERAPEUTICS-INC | 62% | s 4 4 Weighted-average diluted shares outstanding 1,774 1,772 Diluted earnings per share attributable to AbbVie Inc. $ 0.39 $ 0.72 Certain shares issuable under stock-based compensation plans were ex… |
| REMEGEN-CO-LTD | REMEGEN-CO-LTD | 62% | s 4 4 Weighted-average diluted shares outstanding 1,774 1,772 Diluted earnings per share attributable to AbbVie Inc. $ 0.39 $ 0.72 Certain shares issuable under stock-based compensation plans were ex… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| ABBV-DEBT | Debt stack $64.5B | 90% | Market cache reports total debt of $64.5B. |
| ABBV-DEBT-39463 | Debt | 90% | debt detail from 424B5 2026-02-26. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| ABBV-OWNER-VANGUARD-CAPITAL-MANAGEMENT-LLC | VANGUARD CAPITAL MANAGEMENT LLC | 90% | 13F overlay lists VANGUARD CAPITAL MANAGEMENT LLC as top holder; 4080 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| ADGM | Adagio Medical Holdings, Inc. | 100.00 | 2 | |
| BCAX | Bicara Therapeutics Inc. | 100.00 | 2 | |
| SNNUF | Smith & Nephew plc | 100.00 | 2 | |
| ALC | Alcon Inc. | 100.00 | 2 | |
| CLGN | CollPlant Biotechnologies Ltd. | 100.00 | 2 | |
| ALDX | Aldeyra Therapeutics, Inc. | 100.00 | 1 | ['supplier'] |
| AVBP | ArriVent BioPharma, Inc. | 100.00 | 2 | |
| HTGC | Hercules Capital, Inc. | 100.00 | 2 | |
| BLLN | BillionToOne, Inc. | 100.00 | 2 | |
| CYTOF | Altamira Therapeutics Ltd. | 100.00 | 2 | |
| ATRA | Atara Biotherapeutics, Inc. | 100.00 | 2 | |
| RGNX | REGENXBIO Inc. | 100.00 | 1 | ['supplier'] |
| AORT | Artivion, Inc. | 100.00 | 2 | |
| BNR | Burning Rock Biotech Limited | 100.00 | 2 | |
| BNRG | Brenmiller Energy Ltd | 100.00 | 2 | |
| AMGN | Amgen Inc. | 100.00 | 2 | |
| AZN | AstraZeneca PLC | 100.00 | 2 | |
| ANIK | Anika Therapeutics, Inc. | 100.00 | 2 | |
| CSTE | Caesarstone Ltd. | 100.00 | 2 | |
| ACIU | AC Immune SA | 100.00 | 2 |